The FAA administrator's comments come on the eve of his visit to Boeing facilities outside Seattle, Washington. While there, he's scheduled to meet with Boeing executives and...Airlinesread more
CBS, CNN and other major media companies are starting to pull e-cigarette advertising off their airways, as the death toll from a mysterious vaping-related illness continues...Health and Scienceread more
Investors largely expected the FOMC to cut rates by a quarter point.The Fedread more
As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
For the past six years, Facebook has tried over and over to release a hardware product that consumers will want, and it has never succeeded.Technologyread more
AT&T is considering selling DirecTV, according to a report in the Wall Street Journal.Technologyread more
The Fed cut interest rates by a quarter point, but it also reaffirmed its rate cut was meant to serve as insurance for the economy.Market Insiderread more
President Barack Obama spoke at an event in San Francisco on Wednesday hosted by software company Splunk and addressed how tech can help solve problems.Technologyread more
Disney CEO Bob Iger writes in his autobiography that he believes he would have discussed combining Disney with Apple had Steve Jobs lived.Technologyread more
The Facebook CEO will talk to policymakers "about future internet regulation," according to a spokesperson.Technologyread more
Microsoft shares rose 1% after hours as it announced plans to raise its dividend and authorized as much as $40 billion to buy back shares.Technologyread more
Gottlieb resigned from the FDA this spring after nearly two years at the helm. During his tenure, Gottlieb advanced a number of prescription drug policies, including to push the FDA to speed up generic drug approvals and use its powers to encourage wider use of biosimilars, or copycat versions of complex and often costly biologic drugs.
Biosimilar manufacturers, including Pfizer, have complained about roadblocks stalling biosimilars from becoming widely used. Having Gottlieb to advise the company could help Pfizer, one of the largest biopharmaceutical companies, navigate the landscape.
CEO Albert Bourla, who succeeded Ian Read on January 1, shuffled the company's senior management team last year and is leading the effort to restructure the pharmaceutical giant into a more nimble company. Pfizer announced plans last July to reorganize into three units, separating out its consumer healthcare business that it had been trying to sell.
"We are fortunate to have Dr. Gottlieb join Pfizer's Board of Directors," Pfizer Executive Chairman and former CEO Ian Read said in a statement. "Scott's expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives."
Since leaving the FDA, Gottlieb has returned to the American Enterprise Institute as a resident fellow and as a special partner at venture capital firm New Enterprise Associates, where he worked before joining the FDA. He also joined CNBC as a contributor.
Disclosure: Scott Gottlieb is a CNBC contributor.
—CNBC's Berkeley Lovelace Jr. contributed to this report.